Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Follistatin 344 vs Somapacitan (Sogroya)
An educational, source-based comparison of Follistatin 344 and Somapacitan (Sogroya) — how each peptide works, what it's researched for, and what to know before going deeper.
Myostatin-binding protein fragment researched for muscle growth.
A naturally occurring glycoprotein that binds and neutralizes myostatin and activin, releasing the natural brake on skeletal muscle growth in preclinical models.
- Muscular dystrophy models
- Skeletal muscle hypertrophy
- Age-related sarcopenia (preclinical)
- • Off-target effects on activin signaling (reproductive, cardiac) are a concern.
- • Not FDA-approved; banned by WADA.
Once-weekly growth hormone analog for adults and children with GHD.
GH analog with a non-covalent albumin-binding side chain that extends half-life, enabling once-weekly subcutaneous administration with sustained IGF-1 elevation.
- Adult growth hormone deficiency
- Pediatric GH deficiency
- • FDA-approved.
- • Monitor glucose; injection-site reactions possible.
Follistatin 344 vs Somapacitan (Sogroya) — Key differences
- Class: Follistatin 344 is classified as Muscle · Myostatin Inhibition, while Somapacitan (Sogroya) is GH Analog · Endocrine.
- Primary research focus: Follistatin 344 — muscular dystrophy models; Somapacitan (Sogroya) — adult growth hormone deficiency.
- Tag: Muscle vs FDA-Approved · Endocrine.